Strides Pharma Science Ltd reports Q2FY27 revenue of ₹14,297m, up 17.1% YoY, with EBITDA margin at 17.6%
- EBITDA rose 8.4% YoY to ₹2,509m; reported net profit increased 2.0% to ₹1,341m and included a ₹17m net exceptional loss.
- Ex-US markets grew 31% YoY and exceeded US revenue for the first time.
- H1FY27 revenue was ₹26,951m, EBITDA ₹4,807m at an 17.8% margin, and reported net profit ₹2,996m; net debt rose amid an elongated cash-to-cash cycle.